CardiolRx

New data published in JACC demonstrates CRD-38's ability to improve cardiac function and reduce inflammation through its unique cannabidiol-based mechanism of action.

Cardiol Therapeutics' CardiolRx demonstrated lasting improvements in pericarditis symptoms over a 26-week extension in the Phase II MAvERIC-Pilot study.

Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pericarditis pain and inflammation over 26 weeks in a Phase 2 trial.

Cardiol Therapeutics is advancing its drug, CardiolRx, into a Phase III clinical trial (MAVERIC-3) for recurrent pericarditis after promising Phase II results.

Cardiol Therapeutics' CardiolRx demonstrated sustained pain relief in recurrent pericarditis patients over six months, with average pain scores decreasing from 5.8 to 1.5.